68GA FAPI-04 PET/BT ile Onkolojik Görüntüleme
References
Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193-203. doi: 10.1200/JCO.1994.12.6.1193.
Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002-19. doi: 10.1101/gad.279737.116.
Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12. doi: 10.1074/jbc.274.51.36505.
Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993;53(14):3327-35.
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87(18):7235-9. doi: 10.1073/pnas.87.18.7235.
Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423-1429. doi: 10.2967/jnumed.118.210435.
Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018;59(9):1415-1422. doi: 10.2967/jnumed.118.210443.
Meyer C, Dahlbom M, Lindner T, et al. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020;61(8):1171-1177. doi: 10.2967/jnumed.119.236786.
Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-63. doi: 10.1002/prca.201300095.
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi: 10.2967/jnumed.119.227967.
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z.
Kömek H, Can C, Güzel Y, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35(6):744-752. doi: 10.1007/s12149-021-01616-5.
Ding F, Huang C, Liang C, et al. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021;49(1):290-300. doi: 10.1007/s00259-021-05442-9.
Elboga U, Sahin E, Kus T, et al. Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Ann Nucl Med. 2021;35(12):1321-1331. doi: 10.1007/s12149-021-01672-x.
Promteangtrong C, Siripongsatian D, Jantarato A, et al. Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study. J Nucl Med. 2022;63(8):1155-1161. doi: 10.2967/jnumed.121.262831.
Chen S, Chen Z, Zou G, et al. Accurate preoperative staging with [68Ga] Ga-FAPI PET/CT for patients with oral squamous cell carcinoma: a comparison to 2-[18F] FDG PET/CT. Eur Radiol. 2022;32(9):6070-6079. doi: 10.1007/s00330-022-08686-7.
Qin C, Liu F, Huang J, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48(10):3228-3237. doi: 10.1007/s00259-021-05255-w.
Can C, Kepenek F, Kömek H, et al. Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer. Nucl Med Commun. 2022;43(10):1084-1091. doi: 10.1097/MNM.0000000000001607.
Wang L, Tang G, Hu K, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Advanced Lung Cancer. Radiology. 2022;303(1):191-199. doi: 10.1148/radiol.211424.
Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019;46(8):1754-1755. doi: 10.1007/s00259-019-04346-z.
Li Y, Lin X, Li Y, et al. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study. Mol Imaging Biol. 2022;24(2):309-320. doi: 10.1007/s11307-021-01679-w.
Liu Q, Shi S, Xu X, et al. The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(4):1248-1249. doi: 10.1007/s00259-020-04997-3.
Zhao L, Chen S, Chen S, et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55-61. doi: 10.1016/j.radonc.2021.02.015.
Lin R, Lin Z, Chen Z, et al. [68Ga] Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F] FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49(8):2960-2971. doi: 10.1007/s00259-022-05799-5.
Zhang S, Wang W, Xu T, et al. Comparison of Diagnostic Efficacy of [68Ga] Ga-FAPI-04 and [18F] FDG PET/CT for Staging and Restaging of Gastric Cancer. Front Oncol. 2022;12:925100. doi: 10.3389/fonc.2022.925100.
Chen H, Pang Y, Li J, et al. Comparison of [68Ga] Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2022 Aug 17. doi: 10.1007/s00330-022-09084-9.
Kömek H, Can C, Kaplan İ, et al. Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022;49(11):3898-3909. doi: 10.1007/s00259-022-05839-0.
Huang D, Wu J, Zhong H, et al. [68Ga] Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022 Nov 3. doi: 10.1007/s00259-022-06021-2.
Qin C, Song Y, Gai Yet al. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging. 2022;49(12):4228-4240. doi: 10.1007/s00259-022-05847-0.
Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48(5):1593-1603. doi: 10.1007/s00259-020-05070-9.
Guo W, Pang Y, Yao L, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga] Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604-1617. doi: 10.1007/s00259-020-05095-0.
Siripongsatian D, Promteangtrong C, Kunawudhi A, et al. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F] F-FDG PET/CT in Patients with Liver Malignancies. Mol Imaging Biol. 2022;24(5):818-829. doi: 10.1007/s11307-022-01732-2.
Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics (Basel). 2022;12(8):1958. doi: 10.3390/diagnostics12081958.
Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [68Ga] Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(4):1322-1337. DOI: 10.1007/s00259-021-05576-w .
Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med. 2021;62(6):779-786. DOI: 10.1097/mpa.0000000000001375.
Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(8):2877-2888. doi: 10.1007/s00259-022-05729-5.
Dendl K, Koerber SA, Finck R, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48(12):4089-4100. doi: 10.1007/s00259-021-05378-0.
Dendl K, Koerber SA, Tamburini K, et al. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies. Semin Nucl Med. 2022;52(5):628-634. doi: 10.1053/j.semnuclmed.2022.04.002.
Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002-19. doi: 10.1101/gad.279737.116.
Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12. doi: 10.1074/jbc.274.51.36505.
Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993;53(14):3327-35.
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87(18):7235-9. doi: 10.1073/pnas.87.18.7235.
Loktev A, Lindner T, Mier W, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423-1429. doi: 10.2967/jnumed.118.210435.
Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018;59(9):1415-1422. doi: 10.2967/jnumed.118.210443.
Meyer C, Dahlbom M, Lindner T, et al. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020;61(8):1171-1177. doi: 10.2967/jnumed.119.236786.
Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-63. doi: 10.1002/prca.201300095.
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi: 10.2967/jnumed.119.227967.
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z.
Kömek H, Can C, Güzel Y, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35(6):744-752. doi: 10.1007/s12149-021-01616-5.
Ding F, Huang C, Liang C, et al. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021;49(1):290-300. doi: 10.1007/s00259-021-05442-9.
Elboga U, Sahin E, Kus T, et al. Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Ann Nucl Med. 2021;35(12):1321-1331. doi: 10.1007/s12149-021-01672-x.
Promteangtrong C, Siripongsatian D, Jantarato A, et al. Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study. J Nucl Med. 2022;63(8):1155-1161. doi: 10.2967/jnumed.121.262831.
Chen S, Chen Z, Zou G, et al. Accurate preoperative staging with [68Ga] Ga-FAPI PET/CT for patients with oral squamous cell carcinoma: a comparison to 2-[18F] FDG PET/CT. Eur Radiol. 2022;32(9):6070-6079. doi: 10.1007/s00330-022-08686-7.
Qin C, Liu F, Huang J, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48(10):3228-3237. doi: 10.1007/s00259-021-05255-w.
Can C, Kepenek F, Kömek H, et al. Comparison of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer. Nucl Med Commun. 2022;43(10):1084-1091. doi: 10.1097/MNM.0000000000001607.
Wang L, Tang G, Hu K, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Advanced Lung Cancer. Radiology. 2022;303(1):191-199. doi: 10.1148/radiol.211424.
Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019;46(8):1754-1755. doi: 10.1007/s00259-019-04346-z.
Li Y, Lin X, Li Y, et al. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study. Mol Imaging Biol. 2022;24(2):309-320. doi: 10.1007/s11307-021-01679-w.
Liu Q, Shi S, Xu X, et al. The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(4):1248-1249. doi: 10.1007/s00259-020-04997-3.
Zhao L, Chen S, Chen S, et al. 68Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55-61. doi: 10.1016/j.radonc.2021.02.015.
Lin R, Lin Z, Chen Z, et al. [68Ga] Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F] FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022;49(8):2960-2971. doi: 10.1007/s00259-022-05799-5.
Zhang S, Wang W, Xu T, et al. Comparison of Diagnostic Efficacy of [68Ga] Ga-FAPI-04 and [18F] FDG PET/CT for Staging and Restaging of Gastric Cancer. Front Oncol. 2022;12:925100. doi: 10.3389/fonc.2022.925100.
Chen H, Pang Y, Li J, et al. Comparison of [68Ga] Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2022 Aug 17. doi: 10.1007/s00330-022-09084-9.
Kömek H, Can C, Kaplan İ, et al. Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging. 2022;49(11):3898-3909. doi: 10.1007/s00259-022-05839-0.
Huang D, Wu J, Zhong H, et al. [68Ga] Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022 Nov 3. doi: 10.1007/s00259-022-06021-2.
Qin C, Song Y, Gai Yet al. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging. 2022;49(12):4228-4240. doi: 10.1007/s00259-022-05847-0.
Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48(5):1593-1603. doi: 10.1007/s00259-020-05070-9.
Guo W, Pang Y, Yao L, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga] Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604-1617. doi: 10.1007/s00259-020-05095-0.
Siripongsatian D, Promteangtrong C, Kunawudhi A, et al. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F] F-FDG PET/CT in Patients with Liver Malignancies. Mol Imaging Biol. 2022;24(5):818-829. doi: 10.1007/s11307-022-01732-2.
Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics (Basel). 2022;12(8):1958. doi: 10.3390/diagnostics12081958.
Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [68Ga] Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(4):1322-1337. DOI: 10.1007/s00259-021-05576-w .
Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med. 2021;62(6):779-786. DOI: 10.1097/mpa.0000000000001375.
Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(8):2877-2888. doi: 10.1007/s00259-022-05729-5.
Dendl K, Koerber SA, Finck R, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging. 2021;48(12):4089-4100. doi: 10.1007/s00259-021-05378-0.
Dendl K, Koerber SA, Tamburini K, et al. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies. Semin Nucl Med. 2022;52(5):628-634. doi: 10.1053/j.semnuclmed.2022.04.002.
Pages
15-24
Published
April 3, 2023
Copyright (c) 2023 Academician Book Portal
License
LicenseHow to Cite
1.
Güzel Y. 68GA FAPI-04 PET/BT ile Onkolojik Görüntüleme. In: Kaya Ö, editor. Güncel Radyoloji Çalışmaları III [Internet]. Türkiye: Academician Publishing Book DOI Portal; 2023 [cited 2026 Jul. 16]. pp. 15-24. Available from: https://omp35.books.akademisyen.net/index.php/akya/catalog/book/2545/chapter/12698
